News and events

All Press Releases

2024

Nicox Announces First Commercial Sale of ZERVIATE in China by Partner Ocumension, Creating a New Recurrent Revenue Stream December 4, 2024
Nicox’s Denali Phase 3 Trial of NCX 470 Fully Enrolled in China Earlier than Expected December 2, 2024
Nicox Announces Publication of the Adaptive Design Period of the NCX 470 Mont Blanc Phase 3 Trial November 19, 2024
Nicox Provides Third Quarter 2024 update and First Half 2024 Financial Results October 17, 2024
Nicox and Soleus Sign $16.5 million Royalty and Equity Financing October 14, 2024
Nicox and Glaukos Sign Exclusive NCX 1728 Research and Global Licensing Option Agreement September 23, 2024
Nicox Announces Approval of ZERVIATE in China September 18, 2024
Nicox Appoints Christine Placet to Board of Directors; Michele Garufi steps down from Board September 4, 2024
Nicox Announces Recruitment of Last Patient in U.S. in Denali Phase 3 Trial of NCX 470 July 25th, 2024
Nicox announces attendance at upcoming conferences July 19th, 2024
Nicox Provides Second Quarter 2024 Update July 18, 2024
Nicox appoints experienced biotech leader Damian Marron as Chair of the Board and Marc Le Bozec as Director July 16th, 2024
Nicox: 2024 Ordinary Shareholder Meeting June 27th, 2024
Nicox announces the success of its equity offering with preemptive rights through an issue of stock with warrants, for a total amount of €3.3 million, extending its cash runway to continue the development of NCX 470 June 19, 2024
Nicox announces an equity offering with preemptive rights through an issue of stock with warrants, for up to a maximum of around €3.8 million. The funds will finance the development of NCX 470 and the extension of its cash horizon May 30, 2024
Nicox: 2024 Ordinary Shareholder Meeting to be held on June 28th, 2024 May 24, 2024
Nicox’s Ordinary and Extraordinary Shareholders’ Meeting on May 6, 2024 May 6, 2024
Second notice of the Ordinary and Extraordinary Shareholders’ Meeting on May 6, 2024 and appointment of an ad hoc agent April 24, 2024
Nicox Provides First Quarter 2024, Update and Full Year 2023 Financial Results April 22, 2024
2024 Ordinary and Extraordinary Shareholder Meeting April 9, 2024
Shareholder Letter march 22, 2024
Results from Mont Blanc Phase 3 Trial of Nicox’s NCX 470 in Glaucoma Published in the American Journal of Ophthalmology March 20, 2024
Nicox to Hold Webcast on March 18 on its Corporate Pipeline and Financing Perspectives and Key NCX 470 Clinical Data with Presentation by Leading French Glaucoma Key Opinion Leader March 14, 2024
Nicox Updates on Corporate, Pipeline and Financing Perspectives and Will Hold a Webcast on March 18, 2024 March 13, 2024
Nicox Announces Presentation of Data on NCX 470 at the 2024 American Glaucoma Society Annual Meeting March 5, 2024
Nicox Appoints Experienced Biotech Executive Gavin Spencer as CEO February 28, 2024
Nicox Restructures Debt, Streamlines Operations to Extend Cash Runway and Focus Resources on NCX 470 Pivotal Trial February 28, 2024
Nicox and Kowa Enter into Agreement for NCX 470 Development and Commercialization in Japan February 8, 2024
Nicox announces presentations at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2024 February 6, 2024
Nicox Receives Confirmation of 5-year Patent Term Extension of U.S. Patent for Latanoprostene Bunod, Commercialized as VYZULTA® January 31, 2024
Nicox Provides Fourth Quarter 2023 Financial and Business Highlights January 25, 2024
Nicox : Half-year liquidity contract statement with Kepler Cheuvreux as of December 31, 2023 January 8, 2024
Nicox : Termination of the liquidity contract with Kepler Cheuvreux (January 3rd, 2024) January 3, 2024

2023

Nicox Announces First Patient Screened in the Whistler Phase 3b Trial of NCX 470 in Glaucoma December 18, 2023
Nicox’s Announces Publication of New Nonclinical Data Demonstrating More Effective Intraocular Pressure Lowering of NCX 470 compared to Lumigan December 14, 2023
Nicox Provides First Half 2023 and Third Quarter 2023 Financial Results and Updates Key Milestones October 20, 2023
Nicox Provides Second Quarter 2023 Financial and Business Highlights July 19, 2023
Nicox: Half-year liquidity contract statement with Kepler Cheuvreux (as of June 30, 2023) July 11, 2023
Nicox Estimates Potential Annual Global Net Sales for NCX 470 of over $300 million July 10, 2023
Nicox Presented NCX 470 Phase 3 Mont Blanc Adaptive Design Data and Additional Subset Analysis Showing Superiority over Latanoprost at the World Glaucoma Congress July 3, 2023
Nicox: 2023 Ordinary Shareholder Meeting June 2, 2023
Nicox’s Partner Ocumension Therapeutics Receives Priority Review Status for ZERVIATE New Drug Application in China April 28, 2023
Transfer of Nicox’s shares to Euronext Growth Paris effective on April 28, 2023 April 26, 2023
New Data on Two Nicox’s Assets, NCX 470 and NCX 1728, Presented at ARVO 2023 April 26, 2023
Shareholders Letter – April 2023 April 24, 2023
Nicox: 2023 Ordinary Shareholder Meeting to be held on June 1, 2023 April 24, 2023
Nicox Provides First Quarter 2023 Financial and Business Highlights April 19, 2023
Additional Future Royalty Revenue Stream for Nicox from 2024 following New Drug Application Submission for ZERVIATE in China April 14, 2023
Nicox Announces Presentations of Additional NCX 470 Data at the Upcoming World Glaucoma Congress March 21, 2023
Nicox Reports 2022 Financial Results and Updates Key Future Milestones March 20, 2023
Nicox to Present at Upcoming Scientific Conferences March 3, 2023
Nicox: Ordinary Shareholder Meeting of February 28, 2023 – Approval of all Resolutions March 1, 2023
Nicox’s Ordinary Shareholder Meeting to be held on February 28, 2023 February 13, 2023
Nicox to Participate in Financial, Pharmaceutical Industry and Scientific Events in H1 2023 January 24, 2023
Nicox Provides Fourth Quarter 2022 Financial Highlights January 18, 2023
Nicox Announces Proposed Move to Euronext Growth Paris January 9, 2022
Half-year liquidity contract statement with Kepler Cheuvreux (as of December 31, 2022) January 6, 2023

2022

Nicox Outlines Future Development and Partnering Plans for NCX 470 in Glaucoma November 7, 2022
Nicox Reports Achieving Primary Objective in Mont Blanc, the First Phase 3 Glaucoma Trial for NCX 470 October 31, 2022
Nicox Provides Third Quarter 2022 Financial and Business Highlights October 19, 2022
Nicox Announces Last Patients Complete Final Visit in NCX 470 Phase 3 Mont Blanc Glaucoma Trial September 19, 2022
Nicox Provides First Half 2022 Business Update and Financial Results September 16, 2022
Nicox to Participate in Financial and Scientific Events in Q3 2022 August 3, 2022
Nicox Appoints Jean-Francois Labbé as Chairman of the Board of Directors July 29, 2022
Nicox Provides Second Quarter 2022 Financial and Business Highlights July 20, 2022
Nicox: 2022 Extraordinary Shareholder Meeting July 8, 2022
Nicox Announces Publication of NCX 470 Results Demonstrating Improvements to Ocular Hemodynamics and Retinal Cell Physiology July 7, 2022
Nicox Extraordinary General Meeting of July 11, 2022 June 22, 2022
Nicox: 2022 Ordinary Shareholder Meeting June 14, 2022
Nicox Accelerates Topline Results from NCX 470 Mont Blanc Phase 3 Glaucoma Trial to November 2022 June 3, 2022
Nicox Announces a New Governance Structure May 16, 2022
Nicox: 2022 Ordinary Shareholder Meeting May 4, 2022
Nicox at ARVO 2022: Presentation of clinical Phase 2 results on NCX 4251 and new non-clinical evidence of improved hemodynamic and retinal cell physiology on NCX 470 May 2 2022
Nicox Reports 2021 Financial Results and First Quarter 2022 Financial Highlights and Provides Update on Key Programs and Milestones April 28, 2022
Nicox’s NCX 470 Dolomites Phase 2 Results Published in Journal of Glaucoma April 11, 2022
Nicox’s Partner Fera Pharmaceuticals Obtains Orphan Drug Designation from the U.S. FDA for Naproxcinod for the Treatment of Sickle Cell Disease March 2, 2022
Nicox’s Partner Ocumension Obtains Positive Phase 3 Clinical Trial Results for ZERVIATE® in China March 1, 2022
Nicox Announces VYZULTA Now Commercialized in 7 Territories and Approved in Further 9 Countries February 23, 2022
Nicox Granted New Patent for NCX 4251 in Japan February 22, 2022
Nicox Granted New Patent for NCX 470 in China, Extending Coverage to 2039 February 21, 2022
Nicox’s Positive FDA Meeting Shows Clear Path for NCX 4251 in Dry Eye February 8, 2022
Nicox to Participate in Financial, Pharmaceutical Industry and Scientific Events in H1 2022 January 27, 2022
Nicox Provides Fourth Quarter 2021 Business and Financial Highlights January 21, 2022
Nicox European Patent Seals ZERVIATE Major Market Coverage to 2030 January 5, 2022

2021

Nicox Announces First Patient in China screened in the ongoing NCX 470 Denali Phase 3 Trial in Glaucoma December 16, 2021
Nicox Appoints Doug Hubatsch as new Chief Scientific Officer to lead Clinical and Non-clinical Development December 13, 2021
Nicox restructure l’accord de financement obligataire avec Kreos Capital et lève 15 millions d’euros avec un placement privé December 9, 2021
Nicox’s Positive Post Hoc Results from NCX 4251 Phase 2b Mississippi Trial Suggest Path Forward in Dry Eye Disease November 30, 2021
Nicox is Granted Patent for Blepharitis Product Candidate NCX 4251 in Europe November 17, 2021
Nicox’s NCX 470 Dolomites Phase 2 Results in Glaucoma Patients to be Presented at the AAO 2021 Annual Meeting November 10, 2021
Nicox Provides Third Quarter 2021 Business and Financial Highlights October 19, 2021
Nicox to present at the OIS Glaucoma Virtual Innovation Showcase October 13, 2021
Nicox Launches New Corporate & Investor Website October 4, 2021
Nicox’s NCX 470 Shows Retinal Cell Protection in a Nonclinical Model September 29, 2021
Nicox First Half 2021 Financial Results and Business Update September 27, 2021
Nicox Announces Results from the NCX 4251 Phase 2b Mississippi Blepharitis Trial September 24, 2021
Nicox Provides Second Quarter 2021 Business and Financial Highlights and Strategic Update 16 July 2021
Nicox Appoints Robert N. Weinreb, M.D. and Sanjay G. Asrani, M.D. to its Glaucoma Clinical Advisory Board 13 July 2021
Nicox to Receive $2 Million from Ocumension Therapeutics as Advance Milestone Payment under ZERVIATE® Agreement 05 July 2021
Nicox Announces Last Patient Completed NCX 4251 Mississippi Phase 2b Blepharitis Trial 02 July 2021
Nicox’s NCX 470 Demonstrates Significant Intraocular Pressure Lowering in Dolomites Phase 2 Glaucoma Trial 01 July 2021
Nicox’s Licensee Bausch + Lomb Receives Approval for VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% in the United Arab Emirates 25 June 2021
Nicox’s NCX 470 Dolomites Phase 2 Results in Glaucoma Patients To Be Presented at the World Glaucoma E-Congress 2021 24 June 2021
Nicox’s Completes Pre-Defined Enrollment of NCX 4251 Mississippi Phase 2b Blepharitis Trial 01 June 2021
Nicox partners with Laboratorios Grin to bring ZERVIATE to Mexico 5 May 2021
Nicox’s Licensee Bausch + Lomb Launches VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% in Taiwan and Receives Approval in Qatar 4 May 2021
Nicox Updates on Fera Pharmaceuticals’ Continuing Evaluation of Naproxcinod 30 April 2021
Broadcast live and record in audio format of the Ordinary general meeting and Extraordinary General Meeting of April 28, 2021 (in French) 28 April 2021
U.S. Patent Office Issues Notice of Allowance for Nicox’s Latanoprostene Bunod in Normal Tension Glaucoma 27 April 2021
Nicox’s NCX 4251 Mississippi Phase 2b Blepharitis Trial Reaches 50% Enrollment 23 April 2021
U.S. Patents for Nicox’s Latanoprostene Bunod, Commercialized as VYZULTA®, Eligible for Patent Term Extension 22 April 2021
Nicox Provides First Quarter 2021 Business Update and Financial Highlights 19 April 2021
BAUSCH HEALTH ANNOUNCES VYZULTA® (LATANOPROSTENE BUNOD OPHTHALMIC SOLUTION), 0.024%, IS NOW APPROVED IN BRAZIL 16 April 2021
Nicox: 2021 Ordinary and Extraordinary General Meetings postponed to April 28, 2021 13 April 2021
Nicox Ordinary and Extraordinary General Meetings of April 14, 2021 26 March 2021
Nicox’s NCX 470 Mont Blanc Phase 3 Glaucoma Trial Reaches 50% Enrollment Milestone 23 March 2021
Nicox: 2021 Extraordinary and Ordinary Shareholder Meetings 5 March 2021
Nicox’s NCX 470 Receives Approval by Chinese Authorities for Local Start of Denali Phase 3 Trial 4 March 2021
Nicox Announces 2020 Financial Results and 2021 Key Milestones March 1, 2021
Nicox Announces the Publication in Leading Scientific Journal of Pre-Clinical Efficacy Results on a New Class of Non-PGA NO-donating IOP-Lowering Compounds 23 February 2021
Nicox’s U.S. Licensee Eyevance Expands U.S. Promotion of ZERVIATE® In Agreement with Hikma 15 February 2021
BAUSCH HEALTH ANNOUNCES VYZULTA® (LATANOPROSTENE BUNOD OPHTHALMIC SOLUTION), 0.024%, IS NOW APPROVED IN SOUTH KOREA 9 February 2021
Nicox Amends Bond Financing Agreement with Kreos to Provide Financial Flexibility in 2021 29 January 2021
Nicox Analyst Coverage Initiated by Edison Investment Research 22 January 2021
Nicox Provides Fourth Quarter 2020 Business Update and Financial Highlights 20 January 2021
Nicox’s Licensee Bausch + Lomb Launches VYZULTA in Mexico 6 January 2021
Nicox Highlights Successful 2020 Development Progress and Clinical Milestones for 2021 5 January 2021

2020

Nicox’s Partner Ocumension Therapeutics Initiates ZERVIATE Phase 3 Clinical Trial in China 30 December 2020
Nicox’s Licensee Bausch + Lomb Secures Approval of VYZULTA® in Colombia 22 December 2020
Nicox Initiates Phase 2b Trial of NCX 4251, a Potential First-in-Class Treatment for Blepharitis 15 December 2020
Nicox’s Partner Fera Pharmaceuticals to Investigate Naproxcinod as Potential Covid-19 Adjuvant Treatment 11 December 2020
Nicox Analyst Coverage Initiated by Kepler Cheuvreux 25 November 2020
Nicox’s Licensee Bausch + Lomb Launches VYZULTA® in Argentina 23 November 2020
Nicox Initiates Second Phase 3 Trial of NCX 470 in Glaucoma 10 November 2020
Nicox Granted New Patent for NCX 470, Extending Exclusivity in Europe to 2039 29 October 2020
Nicox’s NCX 470 Receives Approval by Chinese Authorities for Local Start of Mont Blanc Phase 3 Trial 26 October 2020
Nicox Selects Development Candidate in a New Class of NO-mediated Intraocular Pressure (IOP) Lowering Agents 23 October 2020
Nicox Announces Third Quarter 2020 Business Update and Financial Highlights 20 October 2020
BAUSCH HEALTH ANNOUNCES VYZULTA (LATANOPROSTENE BUNOD OPHTHALMIC SOLUTION), 0.024%, IS NOW APPROVED IN SEVEN COUNTRIES 24 September 2020
Nicox Selects 0.1% NCX 470 Dose in Adaptive Stage of Mont Blanc Phase 3 Glaucoma Trial September 23, 2020
Nicox’s ZERVIATE Receives IND Approval in China 22 September 2020
Nicox Announces Senior Management Change 18 September 2020
Nicox First Half 2020 Financial Results and Business Update 10 September 2020
Nicox Partners ZERVIATE™ in the Gulf and Arab Markets 12 August 2020
Nicox: Implementation of a liquidity contract with Kepler Cheuvreux 05 August 2020
Nicox Negotiating €2 million Non-Dilutive Loans Guaranteed by the French State 05 August 2020
Nicox Receives €5 Million Upon Closing of VISUfarma Divestment 31 July 2020
Nicox Second Quarter 2020 Business Update and Financial Highlights 17 July 2020
Nicox Reports on Enrollment Progress in Mont Blanc Phase 3 Clinical Trial in Glaucoma 15 July 2020
Nicox Strengthens Cash Position With Divestment of its VISUfarma Shareholding 10 July 2020
Nicox Partner Ocumension Completes Successful Hong Kong IPO at an approximately US$1,090 Million Valuation 10 July 2020
Nicox to Host Key Opinion Leader Call on NCX 470 for the Treatment of Glaucoma 18 June 2020
Nicox Initiates First Phase 3 Trial of NCX 470 in Glaucoma 02 June 2020
Nicox First Quarter 2020 Business Update and Financial Highlights 17 April 2020
Nicox Outlines Plans to Progress NCX 4251 into Phase 2b Trial Following Positive Meeting with FDA 08 April 2020
Nicox’s Partner Fera Pharmaceuticals Files Application for Orphan Drug Designation for Naproxcinod in Sickle-Cell Disease 02 April 2020
Nicox Announces ZERVIATE Launch by Partner Eyevance Pharmaceuticals in the United States 31 March 2020
Nicox Updates on ZERVIATE Progress in China and Expands the Countries of its Agreement with Ocumension Therapeutics 11 March 2020
Nicox to Receive €15 Million and Half of the Cost of the Second NCX 470 Phase 3 Clinical Trial from Ocumension Therapeutics under Amended Agreement 11 March 2020
Nicox’s Partner Secures Additional Approval of VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% in Taiwan 09 March 2020
Nicox Announces 2019 Financial Results and 2020 Key Milestones 06 March 2020
Nicox’s Positive End-of-Phase 2 Meeting with the U.S. FDA Sets Stage for NCX 470 Phase 3 Program in Glaucoma 05 March 2020
Nicox Receives Formulation Patent Extending NCX 470 U.S. Patent Coverage to 2039 03 February 2020
Nicox Fourth Quarter 2019 Business Update and Financial Highlights 21 January 2020
Nicox’s Partner Secures Additional Approvals of VYZULTA (latanoprostene bunod ophthalmic solution), 0.024% in Hong Kong and Argentina 16 January 2020
Nicox’s Partner Secures Approval of VYZULTA in Mexico 13 January 2020

Cookies

By continuing to use this website, you agree to our Cookie Policy.